Event in Progress:
Discover the latest content that has just been published on Research Tree
The Q3 results topped expectations, with strong growth witnessed across the targeted therapeutic areas. Consequently, the management upgraded its 2023 guidance for the third time this year. The ytd gain in the Novartis share price (amongst the top performing AV Big Pharmas) could see further support in the event that the company continues to utilise its balance sheet strength to pursue inorganic opportunities, especially considering the cardiovascular drug Entresto’s upcoming patent expiries. Ov
Companies: Novartis AG
AlphaValue
Novartis exceeded the street’s expectations in the Q2 23, driven by strong growth in Cardiovascular, Oncology and Neuroscience, which more than compensated for Immunology’s soft quarter. Consequently, the full-year guidance was upgraded ‘again’. Given the dearth of suitable acquisition targets, the firm announced $15bn of share buybacks. Overall, Novartis remains a beneficiary of the healthy growth prospects in its target areas, and a cash-rich balance sheet, which also underpins our positive st
Novartis’ Q1 results were ahead of the street’s expectations, with solid performances across all franchises, except Immunology, for which a weaker quarter was largely expected. Given the strong Q1 momentum, 2023 guidance was upgraded. Moreover, despite the share price rally in the last one month, we reaffirm our positive recommendation for Novartis, underpinned by the healthy growth prospects in its targeted areas and a sturdy balance sheet, which paves the way for inorganic growth options as we
Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren
Companies: PIN HAT ME AVO APAX 4503 BHC 4568 FCSS GLXO HLUNB HIK HZNP IBT JAZZ JAZZ JNJ JNJ 4578 REGN REGN STX 4507 4506 4502 TEVA UTHR UTHR VRTX VRTX VTRS UCB UCB SAN SAN PFE PFE PFIZ NOVOB NOVOB NOT MRNA MRNA MRK
Hardman & Co
Novartis delivered a mixed set of results for the last quarter as it failed to meet the revenue expectations of Wall Street but managed an earnings beat. The management continued to invest in the organic business, pursued value-creating bolt-ons, and looked at the full range of M&A opportunities. Their Phase III APPOINT research continues to progress well. Afterward, they moved forward with various indications, including IgAN and C3G, which is anticipated to read out in 2023. To further extend t
Baptista Research
Novartis’ Q4 sales fell short of street expectations, although profitability improvements were noteworthy. The strong performances in Oncology and Cardiovascular were partly offset by weaker dynamics in Immunology and Neuroscience. Generics continued to face pricing pressure. Overall, the continuation of healthy growth for the newer crop of drugs, pipeline execution and ‘all-important’ profitability improvements remain the key for the firm’s much-awaited re-rating.
Novartis’ shares are up c.12% since September 2022, even after yesterday’s c.3% decline post a broker downgrade. The issues triggering yesterday’s correction should not be a cause of major concern. Moreover, Novartis’ investment case is supported by strong growth and/or the attractiveness of its main drugs, intact pipeline execution prowess and healthy balance sheet. While its share price has lagged the likes of Novo and AstraZeneca of late, fortunes could well reverse in the foreseeable future.
This is our first report global pharma major, Novartis. The company delivered a mixed set of results for the last quarter, failing to meet Wall Street expectations in terms of revenues but managing an earnings beat. It saw a 5% top-line growth, also in innovative medicines in Sandoz. The company continues its productive agenda with growth in solid core operating income across the business. In the constant currencies, there has been a continued margin expansion. Novartis continues to gather appro
Q3 sales fell short of consensus and AV estimates while profitability was impacted by one-off charges. However, Innovative Medicines continued its growth/recovery momentum, with healthy growth in all therapeutic areas, except Neuroscience, where Zolgensma had a one-time adverse impact. Sandoz’s guidance upgrade was a positive, especially in the context of rising cost pressure squeezing other players. Overall, we remain positive on the stock, supported by the long remaining patent life of key dru
Novartis again shared a reassuring outlook, with promising sales growth and margin expansion targets. The only difference now is that the firm has clarity on Sandoz and all its efforts can be channelled towards unlocking the potential of its legacy stronghold pharma franchise. Overall, with a good mix of multi-blockbuster assets, a broad-based pipeline – also including some interesting advanced treatment frontier assets, and being open to bolt-ons, Novartis remains on the right track to navigate
Novartis has reported decent Q2 results, with the lynchpin oncology franchise finally reviving. Also, continued strong growth in other major franchises like immunology, cardiovascular and neurology provided additional impetus. Moreover, the improvement in Sandoz’s prospects and upwards revision to the cost-saving targets despite tough external improvement was icing on the cake. Hence, our positive recommendation on the Swiss giant is reiterated.
Novartis started 2022 on a subtle note, with the lynchpin oncology franchise again failing to revive. However, all the other major franchises like immunology and cardiovascular performed well, and covered up for weaknesses/declines in other areas. Importantly, the profitability improvement continued, despite a tough external environment due to the pandemic and geopolitical crisis, which lends further support to our investment case. Hence, our positive recommendation on the Swiss giant is reitera
Novartis has announced a new organisational structure, which is expected to result in further (financial) benefits in the medium-to-long term. Importantly, this rejig is targeted to help the group to become more agile in the face of rapidly-evolving market dynamics. Moreover, reiteration of the mid-term ‘sales + margin’ targets are icing on the cake and should calm the nerves of investors, who have been waiting (patiently) for the firm’s share price revival. Overall, our positive stance on the S
Novartis ended 2021 on a good note, with key drugs (like Cosentyx and Entresto) offsetting weakness and/or restrained growth in other areas. While the 2022 profitability guidance came in lower than our expectations, it was due to sustained troubles in Sandoz – which is already under strategic review. Fortunately, Sandoz is garnering significant interest from various buyers. Overall, with core pharma virtues intact and Sandoz being side-lined gradually, Novartis remains an attractive sector bet.
Novartis has reported largely in line Q3 results, driven by a continuation of the recovery momentum in core pharmas while troubles at Sandoz remained. Fortunately, management has announced a strategic review of Sandoz, which in the long term should result in better return metrics and more effective focus on core competencies, i.e. innovative pharmas. While Novartis remains an attractive but under-rated big pharma bet, the near-term sentiment could (continue to) be mired by the recent DoJ investi
Research Tree provides access to ongoing research coverage, media content and regulatory news on Novartis AG. We currently have 182 research reports from 8 professional analysts.
Cambridge Nutritional Sciences (CNS) has provided a trading update for the 12 months to 31 March 2024, noting that a combination of strong sales growth and significant margin improvements, driven by operational efficiencies, have played key factors in the group’s expectation of being adjusted EBITDA positive in FY 2024. Revenues are expected to be £9.8m (30% YoY growth), ahead of our £9.0m forecast, with gross profits expected to exceed £6m, which is again ahead of our year-end forecast of £5.6m
Companies: Cambridge Nutritional Sciences PLC
Cavendish
Companies: Warpaint London PLC
Shore Capital
Cambridge Nutritional Sciences (CNS) has published its H1 2024 results to end September 2023. Group revenues grew 44% to £4.9m and gross profits increased by 63% to £3.1m, with the company benefitting from newfound operational efficiencies. With its now streamlined strategy focussing on the core Health & Nutrition business and the initial signs of an encouraging uptick in sales momentum, we believe the company is well positioned for growth that will help create future value for shareholders. We
22nd April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acquire the entire issued share capital of 3radi
Companies: ARV CTL AFRN FEN HUW TENG BBSN EAAS VAL
Hybridan
Feature article: Steady as she goes, but could be better: A review of investment company liquidity since 2016 Liquidity is the lifeblood of equity markets. The measurement of liquid asset availability to a market or company is a way of gauging a market’s health. This article builds on our previous work, which analysed the liquidity data for non-financial trading companies, by applying the same analytical techniques to the investment companies (IC) space. We analyse liquidity for ICs as a whol
Companies: NBPE ICGT ARBB RECI CLIG HAT AVO VTA APAX
Companies: IGP RUA BOOM
17th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acquire the entire issued share capital of 3radi
Companies: ARS TIDE SCE SNX ECK CNS TST SPEC SSTY
Venture Life has reported FY23 results to December 2023, following the February trading update. Revenues grew 17% in the year to £51.4m (our est. £50.7m) and adjusted EBITDA was £11.6m (our est. £11.6m). Cash conversion was 85%, generating £9.8m of cash from operations. Cash generation and no M&A in 2023 allowed the company to de-lever, closing FY23 with net debt to adjusted EBITDA at 1.3x. Management have focused on growth with three therapy areas generating double-digit revenue growth and onli
Companies: Venture Life Group Plc
At its recent capital markets day (CMD) and with the support of key opinion leaders, Basilea highlighted the rising need for innovative therapies to address serious fungal and bacterial infections. It continues to make advancements in this specialised segment through the development of opportunistic acquisitions leveraging its anti-infective expertise. Its growth initiatives remain funded through the traction of its commercialised products, Cresemba and Zevtera. FY24 key strategic priorities inc
Companies: Basilea Pharmaceutica AG
Edison
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (
Companies: TXG NDVA TSVT BCOW Z29 TXG NCYT GNS SUN AMS OMG APH EKF EAH IMM AGL DEMG AGY TSTL IPO GDR ETX TRX HVO CTEC AVO OXB DEST VLG IXI VAL INDV AGR AVCT BAI 123F IMCR BCOW
Companies: FOG BOIL BYOT SDI STX
Companies: BILN IGP RBN SBTX
Companies: PureTech Health PLC
Liberum
Creo Medical has received US FDA approval for its Speedboat UltraSlim device, which will enable the company to launch it in the coveted US market. Though expected, this marks a material regulatory win for Creo as UltraSlim is the company’s thinnest and most versatile device and it is now projected to be available in both Europe (via accelerated EU regulatory pathway) and the US in 2024. The UltraSlim device remains an important addition to the portfolio as it provides broader access to gastroint
Companies: Creo Medical Group Plc
Cizzle Biotechnology (Cizzle), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for the early detection of different forms of lung cancer. While implementing this strategy over the past year, Cizzle’s interest has been broadened to include early detection of other cancers and companion diagnostic tests that can assist in the development and use of personalised medicines. In the 12 months since listing, Cizzle has secured key partners
Companies: Cizzle Biotechnology Holdings PLC
Share: